Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Still a Buy?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped up prior to trading on Monday . The stock had previously closed at $10.54, but opened at $11.03. Telix Pharmaceuticals shares last traded at $11.1850, with a volume of 185,091 shares.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Large strategic deal with Regeneron – Telix announced a collaboration with Regeneron to jointly develop and commercialize next‑generation radiopharmaceutical therapies; media coverage values the partnership at up to about $2.1bn, which validates Telix’s platform and boosts commercial upside. Telix and Regeneron Announce Strategic Radiopharma Collaboration
• Positive Sentiment: Phase‑3 clinical milestone — Telix dosed the first patient in the pivotal IPAX‑BrIGHT trial of TLX101‑Tx for recurrent glioblastoma, marking the first radiopharmaceutical to reach Phase 3 in this indication; this advances a high‑value oncology asset toward potential registration. Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial
• Positive Sentiment: Analysts and board momentum — Wedbush and HC Wainwright reaffirmed bullish ratings with $22 and $20 price targets respectively, and Telix expanded its board amid talk of rising valuation and investor interest, all supportive of sentiment. Benzinga Board expansion / valuation piece
• Neutral Sentiment: Convertible bond refinancing — Telix announced refinancing of convertible bonds; this can reduce near‑term refinancing risk but details on pricing/terms determine dilution or interest relief. Telix Refinances Convertible Bonds
• Negative Sentiment: Lingering fundamental misses and leverage — Telix reported a revenue and EPS miss in its prior quarter (Feb 20), and the company carries leverage (debt/equity ~1.08). Those fundamentals can cap enthusiasm and make investors more likely to take profits after positive headlines.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TLX. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Citigroup raised their price objective on Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Monday. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.13.

Telix Pharmaceuticals Stock Down 4.8%

The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The stock has a 50-day simple moving average of $8.05 and a two-hundred day simple moving average of $8.72.

Telix Pharmaceuticals (NASDAQ:TLX) last released its quarterly earnings data on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). The firm had revenue of $206.72 million for the quarter, compared to analysts’ expectations of $421.50 million. Sell-side analysts forecast that Telix Pharmaceuticals Limited will post 0.24 earnings per share for the current year.

Institutional Investors Weigh In On Telix Pharmaceuticals

Large investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its stake in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the period. XTX Topco Ltd bought a new position in Telix Pharmaceuticals in the fourth quarter worth approximately $89,000. OLD Mission Capital LLC purchased a new position in shares of Telix Pharmaceuticals during the 4th quarter worth $111,000. Vident Advisory LLC bought a new stake in shares of Telix Pharmaceuticals during the 4th quarter valued at $204,000. Finally, IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.